SAHAJANAND MEDICAL TECHNOLOGIES LIMITED

15 Oct 2026 - 19 Oct 2026 Main Board BSE NSE

Min Investment

₹14,792.00

Price Band

₹327-₹344

Issue Size

₹335.42 Cr

Lot Size

43 (per lot)

IPO Dates
img

15 Oct 2026

Open Date

img

19 Oct 2026

Close Date

img

21 Oct 2026

Allotment Date

img

23 Oct 2026

Listing Date

Know Before Investing

Strengths icon

  • Strong portfolio of vascular and structural heart medical devices
  • Extensive domestic and international distribution network
  • Dedicated in-house research and development capabilities
  • Multiple manufacturing facilities across India and Thailand
  • Diversified revenue streams from sales in over 65 countries

Weaknesses icon

  • High dependency on revenues from the Supraflex Cruz stent
  • Stringent domestic and global regulatory compliance requirements
  • Vulnerability to foreign currency exchange rate fluctuations
  • Reliance on limited third-party suppliers for key raw materials
  • Exposure to pricing controls and healthcare reimbursement caps

About Sahajanand Medical Technologies Limited

Sahajanand Medical Technologies develops, manufactures, and markets cardiovascular devices globally. The core business is divided into two primary segments: vascular intervention products, such as coronary stents and balloon catheters, and structural heart devices, including transcatheter aortic valves and occluders. The company generates the majority of its revenue from the sale of vascular intervention devices, with the Supraflex Cruz, a biodegradable polymer-based drug-eluting stent, acting as a major contributor to its sales. Products are distributed across India, Europe, and the rest of the world through a combination of direct, hybrid, and distributor-led models, supported by an extensive network of domestic and international distributors. Operations are backed by manufacturing facilities located in Surat, Hyderabad, and Thailand. Additionally, the business relies heavily on dedicated research and development capabilities to continually enhance existing products and introduce new cardiovascular treatments.

IPO Objectives

1. carry out the Offer for Sale of 27,644,231 Equity Shares of face value of ? 1 each aggregating up to ? [?] million by the Selling Shareholders which constitutes

2. 26% of the pre-Offer Equity Share capital of the Company

3. achieve the benefits of listing the Equity Shares on the Stock Exchanges.

Company Promoters

Bhargav Dhirajlal Kotadia

Dhirajlal Vallabhbhai Kotadia

Priyanka Dhirajlal Cohen

Shree Hari Trust

Subscription Details

Investor Category Subscription (times)
Qualified Institutions 34.7
Non-Institutional Buyers 14.64
Retail Investors 3.03
Total 52.37
img

How to Apply for IPO

img img

Login

Login to your Bigul Account

Select Lots & Price

Choose the number of lots and price

UPI ID

Enter your UPI ID

UPI Mandate Request

A UPI Mandate Request Triggered

Approve Mandate

Approve the UPI Mandate Request

IPO Allotment

YES Share will be credited. and the amount will be debited

Close

Let's Open Free Demat Account